拉米夫定耐药,Lamivudine-resistance
1)Lamivudine-resistance拉米夫定耐药
1.102 patients with lamivudine-resistance chronic hepatitis B were randomly divided into control group, IFN-αgroup and combination group.探讨治疗拉米夫定耐药的慢性乙型肝炎的中西医结合疗法。
英文短句/例句
1.The use of entecavir in the treatment of lamivudine-resistant chronic hepatitis B恩替卡韦在拉米夫定耐药患者中的应用
2.Rescue therapy progeress for lamivudine-resistant chronic hepatitis B拉米夫定耐药的慢性乙型肝炎挽救治疗进展
3.Studies on effect of adefovir dipivoxil monotherapy or combination therapy with lamivudine for patients with lamivudine-resistant chronic hepatitis B阿德福韦酯单药或联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究
4.A META-ANALYSIS OF ADEFOVIR DIPIVOXIL ALONE OR IN COMBINATION WITH LAMIVUDINE IN PATIENTS WITH LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B阿德福韦酯单用或联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎的Meta分析
5.A observation on the efficacy of Adefovir dipivoxil combined with Lamivudine for chronic hepatitis B patients with Lamivudine-resistant阿德福韦酯联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎疗效观察
6.Patients with chronic hepatitis B developing lamivudine resistance are at high risk of disease progression and death.对拉米夫定耐药的慢性乙肝患者面临着病情恶化甚至死亡的危险。
7.Character of HBV Polymerase Gene Mutations and Preliminary Observation on the Efficacy of Domestic Adefovir Dipivoxil in Patients with Lamivudine Resistance;拉米夫定耐药患者HBVP基因及用阿德福韦治疗的临床研究
8.Detection of Lamivudine-resistant HBV YMDD Mutants and Investigation of Factors on Clinical Treatment with Lamivudine Correlated with Development of HBV YMDD Mutants;HBV YMDD拉米夫定耐药变异的检测及临床治疗相关因素的分析
9.Clinical Management and Mutational Patterns of Hepatitis B Virus Polymerase Gene in Patients with Lamivudine Resistance;拉米夫定耐药患者乙型肝炎病毒聚合酶基因突变模式及临床处理
10.The Effect of Lamivudine Resistant Associate Mutations to the Sequential Therapy with Other Nucleoside Analogues (NAs);拉米夫定耐药相关突变对其它核苷类似物后续治疗的影响
11.Analysis the Effect of Different Nucleoside (Acid) Analogue Long-term Treatment on Chronic Hepatitis B Patients with Lamivudine-resistant;不同核苷（酸）类似物长期治疗拉米夫定耐药慢性乙肝患者疗效分析
12.The Study of Genes and Structure of Hepatitis B Virus Influencing the Efficiency of Lamivudine and Construction of High Replication Competency, Lamivudine-resistant, Infectious Molecular Clones of HBV;HBV拉米夫定耐药基因结构与功能的研究及感染性克隆的建立
13.Clinical and Laboratory Study on the Chronic Hepatitis B Patients of HBeAg-positive and Lamivudine-resistant with Adefovir Dipivoxil Treatment阿德福韦酯治疗拉米夫定耐药HBeAg阳性的慢性乙肝的临床研究
14.Prevalence of lamivudineresistant hepatitis B virus strains in patients with acute hepatitis B virus infection拉米夫定耐药变异株在急性HBV感染者中的流行调查
15.Rescue treatment of adefovir dipivoxil for lamivudine-resistant CHB patients阿德福韦酯挽救治疗拉米夫定耐药患者的临床分析
16.The hepatitis B viral genotype and mutations of reverse transcriptase domain analysis in patients with lamivu-dine-resistant mutant infection拉米夫定耐药株感染者HBV基因型和逆转录酶区变异分析
17.Nucleotide analogues in treatment of lamivudine-resistant patients with decompensated liver cirrhosis核苷类似物治疗拉米夫定耐药失代偿期肝硬化疗效观察
18.Cost-effectiveness analysis of two methods in the treatment of chronic hepatitis B resistant to lamivudine两组治疗拉米夫定耐药慢性乙型肝炎方法的成本-效果分析
相关短句/例句
Lamivudine-resistant拉米夫定耐药
1.The Curative Effect Observation of Adefovir Dipivoxil forLamivudine-resistant Chronic Hepatitis B(A Report of 126 Cases);阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎126例疗效观察
3)Lamivudine drug resistance拉米夫定耐药性
4)Lamivdine persister拉米夫定耐药株
5)Lamivudine drug-resistant mutation拉米夫定耐药变异
6)Lamivudine-resisrant Hepatitis B拉米夫定耐药性肝炎
延伸阅读
拉米夫定分子式：C8H11N3O3S分子量：暂无CAS号：134678-17-4性质：暂无制备方法：暂无用途：肝胆疾病用药。
